Actively Recruiting

Phase 2
Age: 12Years +
All Genders
NCT04712539

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

Led by M.D. Anderson Cancer Center · Updated on 2026-02-11

60

Participants Needed

1

Research Sites

333 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This phase II trial studies the effect of baloxavir in combination with oseltamivir in treating severe influenza infection in patients who have previously received a hematopoietic (blood) stem cell transplant or have a hematological malignancy. Baloxavir is an antiviral drug that inhibits the growth of influenza virus, reduces viral load and prevents further influenza infection. Osetamivir is an antiviral drug that blocks enzymes on the surfaces of influenza viruses, interfering with cell release of complete viral particles. Giving baloxavir in combination with oseltamivir may shorten or decrease the intensity of influenza infection compared to oseltamivir alone.

CONDITIONS

Official Title

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Hematopoietic cell transplant recipients or patients with hematological malignancy
  • Diagnosed with influenza confirmed by a positive multiplex PCR test
  • Evidence of lower respiratory tract infection or high-risk upper respiratory tract infection, defined by imaging, microbiological evidence, bronchoscopy, biopsy, or immunodeficiency scoring index of 3 or higher or severe neutropenia/lymphopenia
Not Eligible

You will not qualify if you...

  • Requires mechanical ventilation at enrollment
  • Younger than 12 years old
  • Unable to tolerate oral therapy
  • Pregnant at screening (positive serum beta-HCG test for women of child-bearing potential)
  • Taking prohibited medications including influenza antivirals except oseltamivir and baloxavir, or herbal therapies
  • Unable to provide consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

R

Roy F. Chemaly, MD,MPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here